LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) Q3 25 Estimate To -0.60 From -0.59 8/6/2025 10:07:53 AM
  • Wedbush Reiterates Spyre Therapeutics, Inc. (SYRE) At Outperform With $65 Price Target 8/6/2025 10:06:09 AM
  • Spyre Therapeutics Reports Positive Interim Phase 1 Results For Two Next-Generation TL1A Antibody Programs 6/17/2025 7:32:26 AM
  • Wedbush Reiterates Spyre Therapeutics, Inc. (SYRE) At Outperform With $65 Price Target 5/5/2025 10:32:15 AM
  • Spyre Therapeutics Announces Poster Presentations At Digestive Disease Week 2025 5/5/2025 8:13:44 AM
  • Wedbush Reiterates Spyre Therapeutics, Inc. (SYRE) At Outperform With $65 Price Target 1/13/2025 6:09:52 PM
  • Spyre Therapeutics Doses First Participants In Phase 1 Trials Of Novel Half-life Extended Anti-TL1A Antibodies 12/2/2024 8:18:55 AM
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) FY25 Estimate To -3.15 From -3.08 11/12/2024 10:10:15 AM
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) Q4 25 Estimate To -0.76 From -0.74 11/12/2024 10:10:04 AM
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) Q3 25 Estimate To -0.75 From -0.73 11/12/2024 10:09:53 AM
  • Wedbush Is Lowering Spyre Therapeutics, Inc. (SYRE) Q2 25 Estimate To -0.78 From -0.76 11/12/2024 10:09:41 AM
  • Wedbush Is Cutting Spyre Therapeutics, Inc. (SYRE) Q1 25 Estimate To -0.86 From -0.84 11/12/2024 10:09:24 AM